Edition:
India

People: Adamis Pharmaceuticals Corp (ADMP.OQ)

ADMP.OQ on NASDAQ Stock Exchange Capital Market

1.25USD
1:30am IST
Change (% chg)

$-0.03 (-2.34%)
Prev Close
$1.28
Open
$1.30
Day's High
$1.31
Day's Low
$1.24
Volume
57,602
Avg. Vol
66,292
52-wk High
$4.25
52-wk Low
$1.20

Rothermel, Robert 

Mr. Robert B. Rothermel is an Independent Director of Adamis Pharmaceuticals Corporation. Mr. Rothermel is a partner with a private investment and management firm, CroBern Management Partnership, which works within the health care industry. Currently, he serves as a board member and chairman of the audit committee of Medcor, a private healthcare company, and has also served as a board member of Cerescan, a private brain imaging company. Prior to CroBern, Mr. Rothermel spent 37 years with Deloitte & Touche, and served as a Partner and Global Managing Director of the Enterprise Risk Services practice. He also served as a member of Deloitte & Touche’s Board of Directors, the firm’s Global Assurance and Advisory Management Committee, the U.S. Management Committee and chaired the firm’s Partner Compensation Committee. He also served as a director of the Company from January 2004 until its merger with Old Adamis in April 2009 and was Chair of the audit committee of the Company. Mr. Rothermel has a Bachelor of Science degree in Business Administration from Bowling Green State University. .

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Williams

540,000

Dennis Carlo

2,562,760

Robert Hopkins

1,307,310

David Marguglio

1,456,640

Karen Daniels

259,891

Thomas Moll

--
As Of  31 Dec 2017